IDEXX Laboratories, Inc. research snapshot
IDXX AI stock analysis currently reads IDEXX Laboratories as a high-quality veterinary diagnostics and software company with strong recurring CAG diagnostics growth, high margins, and a durable installed-base model, offset by a rich valuation and a still-demanding animal health backdrop. At the August 2, 2026 data cutoff, IDXX traded near $559.07 based on the July 31, 2026 close, with an independently verified market capitalization of about $44.10 billion. Q2 2026 earnings are scheduled for August 4, 2026, so this page reflects Q1 2026 results and current market data. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$559.07
Market cap
$44.10 billion
AI score
78 / 100
Rating
High-quality veterinary diagnostics compounder with premium valuation risk
Trend status
Just above the 50-day moving average, still below the 200-day moving average
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | IDEXX sells veterinary diagnostics, reference lab services, software, imaging, water testing, and livestock diagnostics, with the core CAG model tied to recurring consumables and lab testing. | High |
| Moat | The moat comes from installed instruments, test menus, reference lab scale, clinical workflow integration, data, service relationships, and high customer retention. It is strongest in companion animal diagnostics. | High |
| Management | Mike Erickson has been President and CEO since May 12, 2026, after joining IDEXX in 2011. Jay Mazelsky serves as Executive Chair with a planned May 2027 retirement, so the leadership handoff is in place but still being tested. | Medium-high |
| Financial trend | FY2025 revenue was about $4.304 billion and FY2025 net income was about $1.059 billion. Q1 2026 revenue rose 14% as reported and 11% organic to $1.141 billion, with diluted EPS of $3.47, and trailing twelve-month revenue reached about $4.446 billion. | High |
| Valuation | At $559.07, IDXX traded near 41.13x TTM EPS, 28.47x book value, and about 40.70x free cash flow per share, so even a great business needs sustained growth to justify the price. | High |
| Technical trend | The stock was just above the 50-day moving average near $557.10 but below the 200-day moving average near $620.51, with RSI near 50.86, so the short-term tone is stable but the longer-term trend has not fully repaired. | Medium |
| Risk level | Key risks are premium valuation, uneven veterinary visits, slower instrument placements, new product adoption risk, competitive diagnostics pressure, foreign exchange, buyback timing, leadership transition execution, and the August 4, 2026 Q2 earnings report. | Medium-high |
| AI confidence | High for descriptive research and calculations. Lower for exact return outcomes because a small change in growth expectations or PE multiple can move IDXX materially. | High data confidence |
| Investment certainty | Medium certainty. The business quality is high, but margin of safety is not obvious unless growth and returns on innovation remain strong for several years. | Medium |
IDXX AI stock forecast
The IDXX AI stock forecast uses scenario math around the $559.07 quote and the midpoint of management 2026 EPS guidance near $14.675. The audited three-year framework produced a bearish area near $462, a base area near $703, and a bullish area near $913 before any buyback effect, while the 15-analyst consensus price target stands at $707. The range is wide because IDXX combines high business quality with a valuation that is sensitive to growth and multiple assumptions.
$850 to $940
More likely if EPS compounds near 14% annually, CAG Diagnostics recurring revenue sustains high-single-digit to low-double-digit organic growth, InVue Dx and Cancer Dx adoption deepens the installed base, US clinical visit pressure keeps easing, and the market continues to value IDXX near a premium 42x earnings multiple.
$670 to $730
More likely if EPS compounds near 10% annually, veterinary visit trends gradually improve, pricing and volume support recurring diagnostics, Water and LPD remain smaller stabilizers, and investors value IDXX around 36x forward earnings.
$430 to $490
More likely if vet visits stay weak, instrument placements or new diagnostic menus disappoint, operating margin stalls, currency turns adverse, the CEO transition distracts execution, Q2 2026 results miss, and the market compresses IDXX toward 28x earnings.
IDXX AI technical analysis
IDXX AI technical analysis is mixed as of the August 2, 2026 cutoff. The stock closed at $559.07 on July 31, 2026, just above its 50-day moving average near $557.10 but still below the 200-day moving average near $620.51, with RSI near 50.86. Technical levels should be refreshed with live chart data before trading.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $559.07 | July 31, 2026 close used for market cap and valuation math at the August 2 data cutoff. |
| Near support | $555 to $560 | The 50-day moving average area near $557.10 is the first support band under the current price. |
| Deeper support | $515 to $525 | The area around the lower end of the 52-week range ($518.55) is the deeper downside reference if the rebound fails. |
| Near resistance | $600 to $620 | The first resistance zone sits between round-number supply and the 200-day moving average near $620.51. |
| 50-day moving average | About $557.10 | Price was just above this intermediate trend gauge, which keeps the short-term recovery intact. |
| 200-day moving average | About $620.51 | Price was below this long-term trend gauge, so the broader chart has not fully repaired. |
| Momentum | RSI about 50.86 | Momentum was neutral, with RSI near the middle of the range rather than overbought or oversold. |
| Volume | About 580,000 average daily shares | Breakouts above resistance should be judged against the 20-day average volume because low-volume rebounds can fade. |
| Volatility | Beta about 1.55 | StockAnalysis showed beta above the market average, so position sizing matters around earnings and guidance. |
| Invalidation | Close below $555, then $515 | A close below the 50-day moving average would weaken the rebound. A break into the low $500s would signal a deeper failed setup. |
IDXX AI trading strategy
The IDXX AI trading strategy is a rules-based research framework for a high-quality diagnostics compounder trading at a premium multiple. It is not personal advice and should be paired with live quotes, filings, position sizing, and risk controls.
Watch for IDXX to hold above the 50-day moving average near $557 and reclaim the 200-day moving average near $620 with volume confirmation, stable guidance, and no deterioration in CAG Diagnostics recurring revenue.
A close below about $555 or a failed move at the 200-day moving average should invalidate the short-term setup.
If IDXX pulls back toward the low $500s without a new earnings, product, or veterinary demand shock, compare the price with 2026 EPS guidance, recurring diagnostics growth, and the three-scenario valuation range.
Do not average down without a defined loss limit because high-multiple compounders can keep derating when growth expectations fall.
Track CAG Diagnostics recurring revenue, installed premium instruments, IDEXX VetLab consumables, reference lab volumes, InVue Dx placements, Cancer Dx adoption, Water growth, LPD growth, operating margin, free cash flow, buybacks, the August 4, 2026 Q2 report, and CEO transition execution.
Reduce confidence if EPS growth relies mainly on buybacks or multiple expansion instead of recurring diagnostics volume, price realization, innovation adoption, and operating leverage.
Investment research summary
IDEXX helps veterinarians, animal health customers, and water testing users make faster diagnostic decisions. Customers pay for reliable instruments, consumables, reference lab testing, software workflows, and clinical insight that can improve care and practice productivity.
The moat is strongest in the companion animal ecosystem: installed analyzers pull consumables, reference labs add scale and trust, software supports workflow stickiness, and new test menus make the platform more valuable. It narrows if customers delay visits, competitors match clinical value, or instrument adoption slows.
The thesis fails if veterinary visit weakness becomes structural, pet owners trade down on diagnostics, new platforms underperform, pricing power fades, regulatory or quality issues hit confidence, Q2 2026 results disappoint, or the stock keeps a premium multiple while EPS growth slows.
IDEXX completed a planned CEO succession on May 12, 2026. Mike Erickson, a 15-year IDEXX leader, is now President and CEO, Jay Mazelsky is Executive Chair until his planned May 2027 retirement, and the new CEO is focused on innovation, global expansion, and integrated diagnostics and software. The transition preserves institutional knowledge, but investors still need evidence that innovation pace and commercial execution remain intact.
Pet healthcare benefits from humanization of pets, aging pet populations, higher diagnostic standards, and clinic workflow digitization. The trend is favorable, and Q1 2026 showed a modest easing of US clinical visit pressure, though affordability and visit volumes still matter.
IDXX is priced like a rare compounder. The margin of safety depends less on balance-sheet survival and more on whether recurring diagnostics growth, margin expansion, and innovation can keep earnings compounding fast enough to support a premium PE near 41x.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| IDXX price | $559.07 close on July 31, 2026 | StockAnalysis market data snapshot | August 2, 2026 |
| Market capitalization | $44.10 billion, verified as $559.07 x 78.88 million shares with 0.00% variance | financial_rigor.py market cap verification | August 2, 2026 |
| Shares outstanding | 78.88 million shares, down 2.60% year over year | StockAnalysis statistics | August 2, 2026 |
| FY2025 revenue | $4.304 billion, cross-validated against IDEXX Form 10-K and StockAnalysis | IDEXX 2025 Form 10-K and StockAnalysis | August 2, 2026 |
| FY2025 net income | $1.059 billion from IDEXX Form 10-K; StockAnalysis TTM after Q1 2026 was about $1.10 billion | IDEXX 2025 Form 10-K and StockAnalysis financials | August 2, 2026 |
| Q1 2026 revenue and EPS | $1.141 billion revenue and $3.47 diluted EPS, up 14% as reported and 11% organic | IDEXX Q1 2026 earnings release | August 2, 2026 |
| 2026 guidance | $4.675 billion to $4.760 billion revenue, $14.45 to $14.90 EPS, and 32.1% to 32.5% operating margin | IDEXX Q1 2026 earnings release | August 2, 2026 |
| CAG Q1 2026 revenue | $1.054 billion net CAG revenue, up 14.6% as reported and 11.6% organic, with CAG Diagnostics recurring revenue up 14.1% as reported and 11.0% organic | IDEXX Q1 2026 earnings release | August 2, 2026 |
| Q2 2026 earnings date | Scheduled for August 4, 2026, before market open | StockAnalysis important dates | August 2, 2026 |
| Cash and debt | $200.53 million cash and cash equivalents; about $1.11 billion total debt; net cash position of negative $904.92 million | IDEXX Q1 2026 Form 10-Q and StockAnalysis balance sheet | August 2, 2026 |
| Valuation snapshot | 41.13x TTM PE, 28.47x book value, 40.70x P/FCF, and 2.46% FCF yield from audited inputs | financial_rigor.py valuation verification | August 2, 2026 |
| Analyst consensus | Buy from 15 analysts with an average price target of $707.00 and a 3-year EPS growth forecast of about 12.65% | StockAnalysis forecast | August 2, 2026 |
| Technical snapshot | 50-day moving average about $557.10, 200-day moving average about $620.51, RSI about 50.86, beta about 1.55 | StockAnalysis statistics | August 2, 2026 |
| CEO succession | Mike Erickson became President and CEO effective May 12, 2026; Jay Mazelsky transitioned to Executive Chair with a planned May 2027 retirement | IDEXX CEO succession release | August 2, 2026 |
This IDXX AI stock analysis is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future returns. Forecast scenarios are based on available public data as of August 2, 2026 and may be wrong if IDEXX fundamentals, veterinary visit trends, diagnostics adoption, operating margins, competition, currency, leadership execution, interest rates, or market valuation change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
